What is it about?

This study highlights the importance of Extracorporeal Cytokine Adsorption Therapy (CytoSorb®) in the management of patients with septic shock. We were able to observe 66% of shock reversal when CytoSorb® was used as an adjuvant therapy in addition to standard of care. This paper highlights that CytoSorb® therapy when used early (within less than 24 hours of septic shock) leads to better hemodynamic parameters further leading to better clinical outcome.

Featured Image

Why is it important?

In this present 20th generation, the antibiotics portfolio stands stagnated. CytoSorb® Therapy opens up a new opportunity to regain control in the critically ill patients by addressing the hyperinflammatory condition. In our study, we were able to showcase regaining control in critically ill patients. Further, shock reversal was observed in patients when CytoSorb® Therapy was used early.


Writing this article was a great pleasure as it has co-authors with whom I have long standing collaborations. This article also leads to a conclusion that it seems justified using extracorporeal adsorption therapy (CytoSorb®) early (preferably within less than 24 h after onset of septic shock) as a safe and well tolerated rescue therapy option in patients with septic shock.

Y P Singh

Read the Original

This page is a summary of: Hemoadsorption by extracorporeal cytokine adsorption therapy (CytoSorb®) in the management of septic shock: A retrospective observational study, The International Journal of Artificial Organs, December 2019, SAGE Publications,
DOI: 10.1177/0391398819891739.
You can read the full text:




The following have contributed to this page